Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lashevsky, I.
Right arrow Articles by Markiewicz, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lashevsky, I.
Right arrow Articles by Markiewicz, W.
(Chest. 1996;109:1452-1454.)
© 1996 American College of Chest Physicians

Intrapericardial Minocycline Sclerosis for Malignant Pericardial Effusion

Ilan Lashevsky MD1; Rami Ben Yosef MD2; Diana Rinkevich MD1; Shimon Reisner MD1; and Walter Markiewicz MD1

1 From the Department of Cardiology, Rambam Medical Center, and the Technion-IIT School of Medicine, Haifa, Israel
2 From the Department of Oncology, Rambam Medical Center, and the Technion-IIT School of Medicine, Haifa, Israel

Study objective: To evaluate the effectiveness and safety of minocycline hydrochloride (minocycline) intrapericardially in patients with malignant pericardial effusion.

Design: Consecutive patients admitted to the hospital during a 32-month period received intrapericardial minocycline.

Setting: A 900-bed university hospital.

Patients: Fourteen consecutive patients with malignant pericardial effusion.

Intervention: Following percutaneous insertion of a pericardial drain, minocycline was administered at a dosage of 10 mg/kg every 48 h until fluid drainage stopped or until further therapy was deemed necessary.

Measurements: Complications associated with therapy, total minocycline requirements, immediate and late failure of therapy, and clinical and echocardiographic follow-up of at least 6 months.

Results: Mean amount of minocycline administered was 1.9±1.0 g given in 2.4 divided doses. Total drainage time was 5.4±2.5 days. Recurrence of malignant pericardial effusion was seen in only 1 of 14 patients. Death occurred in 10 patients due to severe metastatic disease in all. Minocycline instillation was associated with severe chest pain in seven patients, and with ECG changes suggesting pericardial or subepicardial injury in two patients.

Conclusion: (1) Intrapericardial minocycline instillation is very effective in preventing recurrence of malignant pericardial effusion. (2) Minocycline is irritative to the pericardium and may cause severe chest pain with transient ECG changes, suggesting pericardial or subepicardial injury.

Key Words: cardiac tamponade • minocycline • pericardial effusion • tetracycline

Submitted on September 12, 1995
Accepted on January 17, 1996




This article has been cited by other articles:


Home page
 ChestHome page
A. Martinoni, C. M. Cipolla, D. Cardinale, M. Civelli, G. Lamantia, M. Colleoni, and C. Fiorentini
Long-term Results of Intrapericardial Chemotherapeutic Treatment of Malignant Pericardial Effusions With Thiotepa
Chest, November 1, 2004; 126(5): 1412 - 1416.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American College of Chest Physicians.